among others, all share a common feature characterized by the loss of particular neuronal populations causing atrophy of specific brain areas. Depending on the brain region affected, the initial symptoms associated with the ND are different. These symptoms could include cognitive impairment, memory loss, speech difficulties and motor dysfunction. However, all diseases progress until reaching a common end stage: patients becoming bed bound, mute, incontinent and unable to take care of themselves, leading finally to their death (Burnstock, 2008; Strafella et al., 2018) .
Despite different toxic factors associated with the etiology of each ND having been identified, little is known about the events that regulate the common molecular mechanisms involved in the neurodegenerative progression. Some of the molecular pathways that contribute to the disease progression include proteasomal dysfunction, neuroinflammation, synaptic alterations, protein aggregation, and oxidative stress.
Although none of them appears to be the primary cause of neurodegeneration, they probably, all act in a synergistic manner promoting neuronal death in a way still unknown.
Over recent years, evidence has suggested that purinergic signaling plays a key role in the aforementioned pathological mechanisms and, therefore, may contribute to ND development. In the present review, we discuss whether the purinergic signaling may be the conductor that coordinates the common molecular mechanisms involved in the neurodegenerative progression.
Purinergic system
Nucleotides behave as neurotransmitters in the central nervous system (CNS), regulating several physiological and pathological processes (Burnstock, 2008) . These compounds activate specific receptors at the plasma membrane denominated P2 purinergic receptors, which are divided into two subgroups: ionotropic P2X and metabotropic P2Y receptors (Burnstock, 2007) . The availability and half-life of the extracellular nucleotides are governed by ectonucleotidases, which sequentially hydrolyze these nucleotides to their corresponding nucleosides (Robson, Sevigny, & Zimmermann, 2006; Zimmermann, Zebisch, & Strater, 2012) 
P2Y receptors
A C C E P T E D M A N U S C R I P T P2Y receptors (P2YR) are metabotropic receptors coupled to G proteins that respond to purine and pyrimidine nucleotides. These receptors have their N-terminal domain oriented towards extracellular space and their C-terminal domain towards the intracellular compartment. Currently, eight different subunits have been cloned and characterized in human or other mammals called P2Y1,2,4,6,11,12,13,14 (Abbracchio, Burnstock, Verkhratsky, & Zimmermann, 2009; Burnstock, 2007) . As a result of their activation through the interaction with G proteins, several intracellular signaling cascades are activated including phospholipase C (PLC), adenylate cyclase (AC), or ion channels (Abbracchio et al., 2009; Ralevic & Burnstock, 1998) . P2YR are widely expressed throughout the organism mediating a multitude of functions (Fischer & Krugel, 2007) . In the CNS, P2YR are expressed in different cellular lineages that make up brain tissue where they regulate a wide variety of physiological processes such as cell proliferation, growth or survival (Khakh & Burnstock, 2009) . Little is known about the role of each P2YR regarding ND.
Among them, a good candidate that could be contributing to the common pathological mechanism of ND is P2Y2 receptor (P2Y2R). P2Y2R has special structural characteristics that allows it to interact with integrins and other receptors which are related to several physiological and pathological phenomena (Weisman, Camden, et al., 2012) . For instance, an upregulation of P2Y2R was found in different cellular and animal models of inflammation and injury (Schrader, Camden, & Weisman, 2005; Shen et al., 2004) , suggesting that this receptor may play a key role in the cellular response to tissue damage . Supporting this idea, P2Y2R activation upregulates antiapoptotic proteins (Chorna et al., 2004) and promotes cellular survival under hyperoxiainduced oxidative stress conditions (Ahmad, Ahmad, Ghosh, Leslie, & White, 2004) or after injury (Burgos, Neary, & Gonzalez, 2007) . Moreover, it has been recently reported that P2Y2R activation modulates the ubiquitin proteasome system (UPS) regulating the expression of β1 and β5 proteasome subunits via an intracellular signaling pathway involving Src/PI3K/MEK/ERK kinases activation de Diego-Garcia et al., 2017) .
P2X receptors
P2X receptors (P2XR) are ligand-gated ion channels inserted into the plasma membrane whose activation causes the selective passage of small size cations (Na + , Ca 2+ ) from extracellular space to the intracellular compartment (Samways, Li, & Egan, 2014) . To date, seven different P2X subunits have been cloned and characterized, from P2X1 to (Vial, Roberts, & Evans, 2004) . These subunits have two transmembrane domains linked by a large extracellular domain, presenting a dolphin-shaped structure with the transmembrane helices and the extracellular region similar to the tail and the body, respectively (Kawate, Michel, Birdsong, & Gouaux, 2009 (P2X7R) is the most studied in relation to ND. P2X7R is currently the only one that has been found as homotrimers in physiological models and it has also been suggested that it can form heterotrimers with P2X4 (Schneider et al., 2017) . Specific features of P2X7R subunit include a large C-terminal domain implicated in an additional channel dilation (Di Virgilio, 1995) , low sensitive to native ligand and sensitivity to extracellular divalent cations (Surprenant, Rassendren, Kawashima, North, & Buell, 1996) . In some peripheral cells, although there is still some controversy, P2X7R stimulation is associated with wider pore opening enabling the passage of molecules of up to 900 Da (Di Virgilio, 1995; Surprenant et al., 1996) (Illes, Khan, & Rubini, 2017) . A recent work using a mouse model overexpressing functional P2X7R tagged to the green fluorescent protein reveals P2X7R expression in microglia, Bergmann glia, and oligodendrocytes, but not in neurons (Kaczmarek-Hajek et al., 2018) P2X7R has been related to several physiological events including neuronal differentiation (Glaser et al., 2014; Messemer et al., 2013; Tsao, Chiu, & Sun, 2013) , axonal growth and branching (M. Diaz-Hernandez et al., 2008) , and neurotransmitter release (Leon, Sanchez-Nogueiro, Marin-Garcia, & Miras-Portugal, 2008; Miras-Portugal et al., 2003; Sperlagh et al., 2002) .
Ectonucleotidases; Alkaline phosphatase
The extracellular actions of nucleotides are limited by the presence of ectonucleotidases which hydrolyze them to obtain the respective nucleoside. Ectonucleotidases belong to several protein families that differ in their functional and molecular properties. These families include ectonucleoside triphosphate diphosphohydrolases, ecto-nucleotide pyrophosphatase/phosphodiesterases, 5´nucleotidase and alkaline phosphatases (AP) (Zimmermann et al., 2012) . Among them, AP constitute a family which, besides hydrolyzing nucleotides also releases inorganic phosphate from a broad spectrum of organic compounds (M. Diaz-Hernandez et al., 2010; Millan, 2006) . AP isozymes are present in both humans and mice (Buchet, Millan, & Magne, 2013) . Three of them, known as the placental, germ cell, and intestinal types are tissue-specific with highly restricted expression, while tissue-nonspecific AP (TNAP) is ubiquitous but particularly abundant in mineralizing tissues, kidneys (Hoshi, Amizuka, Oda, Ikehara, & Ozawa, 1997) and CNS (Fonta, Negyessy, Renaud, & Barone, 2004; Langer et al., 2008; Negyessy et al., 2011) . All isoforms are homodimers sharing an optimum alkaline pH and are anchored to the membrane via a glycosylphosphatidylinositol anchor (Millan, 2006) .
Each monomer contains three metallic ions (two zinc molecules and one of magnesium)
and one phosphate ion (Millan, 2006) . At the CNS, TNAP is present in blood vessels and the neuropil (Langer et al., 2008) as well as in the cortical synaptic densities (Fonta et al., 2004; Negyessy et al., 2011) . In addition to governing the extracellular nucleotide degradation, TNAP has been related to other physiological or pathological processes such as axonal growth, tau toxicity, or biosynthesis of neurotransmitters (Sebastian-Serrano,
de Diego-Garcia, Henshall, Engel, & Diaz-Hernandez, 2018; Sebastian-Serrano et al., 2015) .
Purinergic signaling in Ubiquitin-Proteasome System dysfunction
The UPS mediates the degradation of most of the intracellular proteins in a specific and selective way. UPS plays a relevant role in the degradation of short-lived, regulatory, and misfolded/denatured proteins (Hershko & Ciechanover, 1998) . UPS also regulates numerous and fundamental biological processes such as the progression of the cell cycle, DNA repair, apoptosis, immune response, transduction pathways, transcription, metabolism and protein quality control (Hochrainer & Lipp, 2007) . The proteolysis of the target substrate via UPS occurs in two discrete steps: 1) covalent attachment of multiple
ubiquitin molecules to the protein substrate by the coordinated action of three enzyme families (E1, E2 and E3); 2) degradation of the targeted protein by the proteolytic proteasome complex along with the recycling of free and reusable ubiquitin via deubiquitinating enzymes.
Over the last decade, solid evidence has been accumulated, postulating that an UPS dysfunction may be one of the common molecular mechanism that contributes to the progression of ND (Gadhave et al., 2016) . Indeed, an UPS impairment has been related to the synaptic dysfunction detected on AD, PD or HD (Hegde, 2010) . The characteristic intracellular protein aggregation detected on ND are stained with anti-ubiquitin and antiproteasome antibodies (Schmitt, 2006) suggesting that the UPS is directly or indirectly involved in the pathogenesis of these diseases. There is also genetic evidence supporting the fact that UPS is altered in ND. For example, it has also been described how the mutated ubiquitin UBB+1 found in AD patients, causes an UPS impairment in vitro (Lam et al., 2000) . Point mutations and deletions in the gene encoding the E3 ubiquitin ligase
Parkin lead to the development of the autosomal recessive form of PD (Kitada et al., 1998) . The expansion of repeated CAG triplet that codes for polyglutamine in the deubiquitinating enzyme ataxin-3 causes spinocerebellar ataxia (SCA) type 3 (Yamada, Tan, Inenaga, Tsuji, & Takahashi, 2004) .
Recent works point to the purinergic signaling regulating UPS. In particular, P2Y2R activation is able to induce an increase in the chymotrypsin-like and postglutamyl-like proteasome activities by enhancing the expression of their catalytic proteasome subunits β5 and β1, respectively de Diego-Garcia et al., 2017) . The intracellular signaling pathway underlying these changes involves the Src, PI3K and ERK activation (de Diego-Garcia et al., 2017) . Moreover, subsequent publication has reported that the in vivo administration of selective P2Y2R agonist causes a significant improvement of the UPS activity in neural cells .
Considering the significant reduction in the P2Y2R expression levels found both in AD human patients (Lai et al., 2008) as well as in AD mouse models (Ajit et al., 2014) , it would be reasonable to think that the downregulation of P2Y2R could contribute to the progressive UPS dysregulation associated with the ND progression. In complete agreement with this hypothesis, selective deletion of P2Y2R in a TgCRND8 mouse model of AD accelerates the pathology onset leading to the premature death of these mice at 5 weeks of life (Ajit et al., 2014) . Furthermore, it was reported that the reduction in P2Y2R
levels correlates both with the decrease of neuropathologic scores and the loss of synaptic markers in AD patients (Lai et al., 2008) .
Purinergic signaling in neuroinflammation
As previously mentioned, another feature of ND is a general neuroinflammation, maintained over time (Gahtan & Overmier, 1999) . Neuroinflammation is an inflammatory response within the brain caused by the production of cytokines (IL-1β, IL-6, and TNF-α), chemokines (CCL2, CCL5, CXCL1), secondary messengers (nitric oxide (NO) and prostaglandins) and reactive oxygen species (ROS). These mediators are Moreover, P2X7R is also involved in the release of inflammatory cytokines like IL-1 family, IL-2, IL-6 and IL-18 (Idzko, Ferrari, & Eltzschig, 2014) . Despite microglial cells being the main source of P2X7R dependent IL-1β release, neurons can also release it (Idzko et al., 2014) . Interestingly, it has been described that P2X7R activation also
favours other processes related to inflammation such as the translocation of nuclear factor kappa-light-chain-enhancer of activated B cells, or the Nuclear factor of activated T-cells (Ferrari et al., 1997) and release of the endothelial growth factor (Adinolfi et al., 2012) .
Recently, it has been reported that a potent P2X7R-antagonist [ 11 C]-A-740003 has been used as a novel tracer of neuroinflammation (Adinolfi et al., 2012) . In complete agreement with these results, P2X7R antagonists have been proposed as a promising antineuroinflammatory drugs (Chessell et al., 2005; Mehta et al., 2014; Takenouchi et al., 2010 ).
On the other hand, different publications have found that P2Y2R is upregulated in neuroinflammation Eun et al., 2014) . Hence, it has been postulated that this receptor plays a role on this phenomena (Weisman, Camden, et al., 2012) . Supporting this hypothesis, it has been found that P2Y2R activation potentiates the transendothelial migration of neutrophils (Kukulski et al., 2010) , promotes the secretion of proinflammatory factors from macrophages (Eun et al., 2014) and regulates the migration and phagocytic ability of microglia (Sunkaria, Bhardwaj, Halder, Yadav, & Sandhir, 2016) . However, other studies have reported that P2Y2R activation attenuates the microglial activation (Boucsein et al., 2003) and protects mice from LPS-induced neuronal death (Guerra et al., 2003) . In agreement with this idea, it has been described that a reduction of the P2Y2R genetic load in an AD mouse model promotes both decrease on the expression of the microglial marker CD11b and increases the number of amyloid plaques. These results suggest that P2Y2R plays a relevant role in the recruitment and activation of microglial cells and promotes the microglia-mediated clearance of Aβ (Ajit et al., 2014) . In accordance with these anti-inflammatory properties, nucleotides via P2Y2R attenuate the LPS-induced production of cytokines and NO in macrophages (Guerra et al., 2003) , reduce the release of TNF-, IL-6, and NO in microglial cells (Boucsein et al., 2003) and downregulate the expression of CD14 myeloid differentiation factor 88 caused by LPS-induced TLR4 activation (Xiao et al., 2012) . These data would suggest that the reduction in P2Y2R levels detected in AD patients may be contributing to the maintenance of the neuroinflammatory state in this disease. Interestingly, it was recently reported that LPS-induced neuroinflammation causes an UPS impairment in glial cells by blocking P2Y2R . Moreover, in vivo pharmacological activation of P2Y2R by its specific agonist diuridine tetraphosphate reversed the astrocytic UPS impairment by promoting the expression of the proteasomal β5 subunit . This study provides the first direct evidence
that a specific P2Y2R agonist might have anti-inflammatory properties (de Diego Garcia et al., 2018).
Purinergic signaling and protein aggregation
The presence of aberrant protein aggregates is a common pathological hallmark in patients with ND. Although, initially, intra or extracellular aggregates were postulated as the main cause of the cellular toxicity and dysfunction observed in ND, however, in some cases it is impossible to assert that those are not a consequence of the disease ( (Leon-Otegui et al., 2011) . In agreement with these works, a reduction in the genetic load of P2Y2R in TgCRND8 mice led to a significant increase in Aβ plaque load and soluble Aβ1-42 levels in the cerebral cortex and hippocampus. This increase resulted in consequent acceleration of pathology
onset, leading to the premature death of mice at 5 weeks (Ajit et al., 2014) . In human AD patients, a significant reduction of neocortical P2Y2R levels was found which correlates with the reduction of neuropathologic scores and the loss of synaptic markers (Lai et al., 2008) .
In contrast, P2X7R is upregulated in patients with AD (E. Martin et al., 2018; McLarnon, Ryu, Walker, & Choi, 2006) . P2X7R upregulation takes place mainly in the microglia surrounding the amyloid plaques (McLarnon et al., 2006; Parvathenani et al., 2003) , and the activation of microglial cells by Aβ peptide requires the expression of P2X7R in these cells (Sanz et al., 2009) 2014; E. Martin et al., 2018) . Considering that both APP processing pathways occur in the CNS (Hardy & Selkoe, 2002) , and that the non-amyloidogenic pathway is predominant in the healthy brain (Tyler, Dawbarn, Wilcock, & Allen, 2002) it would be possible to hypothesize that an abnormal increase in extracellular nucleotide concentration favouring the P2X7R signaling might be one of the main factors leading the shift to the amyloidogenic pathway in sporadic AD (Stockley & O'Neill, 2008) .
Purinergic signaling and disease propagation
Over recent years, evidence has emerged suggesting that aggregated proteins spread from one cell to another, behaving like seeds that prompt protein to cause misfolding and aggregation in healthy cells (Walker & LeVine, 2012) . This theory may explain the gradual progression of the pathology associated with ND. For instance, neuropathological hallmarks such as neurofibrillary tangles (NFTs) in AD initially appears in a specific brain area and later spreads to anatomically connected brain regions. The NFTs associated toxicity has a distinct and reproducible pattern, even though the specific mechanisms involved remain unknown. The hyperphosphorylated tau, a main component of NFTs, appears first in the entorhinal cortex and spreads to connected regions like the
hippocampus. In these brain regions, a high relationship between the incidence of tangles and neuronal death is found (Bondareff, Mountjoy, Roth, & Hauser, 1989; Cras et al., 1995) . , 2010) . Furthermore, a preclinical assay, which was tested on more than 100 AD patients showed that TNAP activity is significantly increased in the hippocampus of AD patients compared to their age-related controls, independent of whether they were diagnosed as sporadic or genetic AD. This study also showed high TNAP levels in the plasma of the AD patients (Vardy, Kellett, Cocklin, & Hooper, 2012) , suggesting that TNAP might be a good biomarker of disease progression.
Purinergic signaling and synaptic alterations detected in ND.
A C C E P T E D M A N U S C R I P T Synaptic alterations might also play a relevant role in the ND progression. This hypothesis is based on the extensive synapsis loss found in the brain of human patients presenting ND (DeKosky & Scheff, 1990) . Moreover, the initial toxicity focused on a specific brain area spread to other anatomically connected areas. The initial phases of ND are characterized by neuronal dysfunction associated with a decrease in neuronal volume and arborization; increased fiber density in the specific affected area, and synaptic alterations detected previously to neuronal loss (Burnstock, 2008; Strafella et al., 2018) . All this evidence leads us to believe that synaptic dysfunction is contributing to disease progression. In agreement with this hypothesis, altered presynaptic signaling mediated by P2X7R was detected in two different HD mouse model (M. Diaz-Hernandez et al., 2009) .
In vivo administration of two selective P2X7-antagonists, Brilliant Blue G and A438079
to HD mice models prevents neuronal apoptosis and attenuates body weight loss and motor-coordination deficits. Therefore, these data strongly suggest that alteration of Considering that TNAP promotes axonal growth and branching (Diez-Zaera et al., 2011) , the increased TNAP expression detected in the brain of AD patients might be considered part of the physiological response to counteract the pruning of synaptic contacts detected in this disease. TNAP also regulates the metabolism of several compounds involved in synaptic functionality. For instance, this ectoenzyme governs the intracellular concentration of pyridoxal 5´-phosphate (Fedde & Whyte, 1990) , a cofactor of GAD65 (D. L. Martin & Barke, 1998) essential for gamma-aminobutyric acid (GABA) synthesis.
Among other functions, this compound promotes the tau phosphorylation via GABAA receptor (Nykanen, Kysenius, Sakha, Tammela, & Huttunen, 2012) . In this line, an increased TNAP expression may promote the synaptotoxicity led by the phosphorylation of intracellular tau. Furthermore, TNAP regulates the nucleotide-mediated signaling (Sebastian-Serrano et al., 2015) by which the vesicular release of numerous
neurotransmitters such as acetylcholine, glutamate may be controlled, or GABA (M. Diaz-Hernandez et al., 2002; Gomez-Villafuertes et al., 2001; Gualix et al., 2003) and favors amyloid processing of APP (J. I. Diaz-Hernandez et al., 2012) . Therefore, TNAP alterations may result in nucleotide signaling alterations that would finally give rise to the synaptopathy detected in the AD.
Purinergic signaling and Oxidative Stress
Reactive Oxygen Species (ROS) are chemically reactive molecules that have been associated with the molecular mechanism involved in ND. Despite these compounds being naturally generated, high concentrations could lead to cell death or oxidative stress, a condition where the balance between pro-oxidative and antioxidant levels is disrupted (Zuo, Zhou, Pannell, Ziegler, & Best, 2015) . High levels of ROS are commonly observed in the brains of patients with ND (Albers & Beal, 2000) . Although ROS are not a triggering factor of ND, they can exacerbate the ND progression through the oxidative damage and interacting with the mitochondria (Dias, Junn, & Mouradian, 2013) . Under physiological conditions, ROS generated by mitochondria such as NADPH oxidase and xanthine oxidases are controlled by endogenous antioxidants keeping them in low levels (Zuo et al., 2015) . However, an abnormal mitochondrial function can result in an aberrant ROS levels. In ND, different factors can lead to a mitochondrial dysfunction. For example, in HD, mutant huntingtin may directly interact with mitochondria, increasing the ROS levels (Ross & Tabrizi, 2011) . On the other hand, in PD, the aggregation of -synuclein, a key protein implicated in PD pathogenesis, can interrupt mitochondrial complex-I activity, resulting in mitochondrial dysfunction (Ganguly, Chakrabarti, Chatterjee, & Saso, 2017) . ROS associated with this mitochondrial dysfunction would contribute to the characteristic dopaminergic neuronal loss observed in PD (Dias et al., 2013; Meiser, Weindl, & Hiller, 2013) . Interestingly, it has been reported that extracellular -synuclein co-precipitates with P2X7R in microglia cells. Moreover, this interaction induces the activation of NADPH oxidase that increases the production of ROS causing oxidative stress and increasing the cell death (Jiang et al., 2015) .
In opposition to the P2X7R pro-oxidative effect, other studies have reported that ATP, through P2YR, increases the resistance of astrocytes and neurons to oxidative stress induced by tert-butyl hydroperoxide. This neuroprotective effect is mediated by a Ca 2+ -dependent increase in mitochondrial metabolism (Wu et al., 2007) . Interestingly, oxidative stress induces a shift in purine catabolism, favouring breakdown to xanthine
and the antioxidant uric acid, suggesting that oxidative stress may trigger a negativefeedback mechanism promoting antioxidant defenses (Yao et al., 2010) .
Conclusions
In the present review, a substantial body of evidence has been collected, suggesting that extracellular nucleotides, via their specific P2X7R and P2Y2R, modulate some of the molecular mechanisms by which ND progress toward the common final stage. In such physiological conditions, the P2Y2R activation is shown to promote UPS activity, generate non-aggregated protein form, cause the upregulation of anti-apoptotic proteins and attenuate microglial activation. However, in pathological conditions associated with a significant increase of nucleotides on the extracellular space, the P2X7R activation is promoted. This fact correlates with oxidative stress, neuroinflammation, reduction in the axonal growth ratio and the generation of protein species that tend to aggregate (like amyloid peptide). Alteration of TNAP functionality, in addition to causing an imbalance of the extracellular nucleotide concentration that may lead to the mechanisms mentioned above being affected (Sebastian-Serrano, de Diego-Garcia, Henshall, et al., 2018) , may also promote, by itself, the spread of ND. Altogether, these data suggest that therapeutic strategies seeking to reestablish the basal tone of purinergic signaling might be useful to prevent the progression of the ND and increase the life expectancy of these patients. For instance, the combination of selective P2X7R antagonists and TNAP inhibitors plus specific P2Y2R agonists may result to be useful in the treatment of the AD patients. 
